Table 1. Clinicopathologic features of gastric ‘pure' DLBCL with and without HP infection.
| Variable | Total (%) | HP positive (%) | HP negative (%) | P-value |
|---|---|---|---|---|
| Total no. | 95 (100) | 46 (48) | 49 (52) | |
| Sex | ||||
| Female | 52 (55) | 23 (50) | 29 (59) | 0.369 |
| Male | 43 (45) | 23 (50) | 20 (41) | |
| Age (years old) | ||||
| <60 | 43 (45) | 20 (44) | 23 (47) | 0.735 |
| ⩾60 | 52 (55) | 26 (56) | 26 (53) | |
| Endoscopic features | ||||
| Ulceration or ulcerated mass | 54 (57) | 31 (67) | 23 (47) | 0.044 |
| Non-ulcerative lesionsa | 41 (43) | 15 (33) | 26 (53) | |
| Location of tumor (s) | ||||
| Proximal or ⩾2 components | 49 (52) | 19 (41) | 30 (61) | 0.052 |
| Distal | 46 (48) | 27 (59) | 19 (39) | |
| Presence of B symptoms | ||||
| Yes | 16 (17) | 3 (6) | 13 (27) | 0.009 |
| No | 79 (83) | 43 (94) | 36 (73) | |
| Stage | ||||
| I-IIE1 | 51 (62) | 32 (70) | 19 (39) | 0.003 |
| IIE2/III/IVb | 44 (38) | 14 (30) | 30 (61) | |
| ECOG | ||||
| 0–1 | 80 (84) | 42 (91) | 38 (78) | 0.066 |
| ⩾2 | 15 (16) | 4 (9) | 11 (22) | |
| LDH | ||||
| Normal | 53 (56) | 31 (67) | 22 (45) | 0.027 |
| High | 42 (44) | 15 (33) | 27 (55) | |
| IPI risk group | ||||
| 0–1 | 51 (54) | 30 (65) | 21 (43) | 0.029 |
| ⩾2 | 44 (46) | 16 (35) | 29 (57) | |
| Chemotherapy response | ||||
| pCR | 58 (61) | 35 (76) | 23 (47) | 0.004 |
| PR+SD+PDc | 37 (39) | 11 (24) | 26 (53) | |
| Histologic subclassification (n=78) | ||||
| GCB | 44 (56) | 25 (64) | 19 (49) | 0.171 |
| Non-GCB | 34 (44) | 14 (36) | 20 (51) | |
| Chemotherapy regimen | ||||
| Anthracycline-basedd | 61 (64) | 26 (57) | 35 (72) | 0.511 |
| Rituximab/anthracycline-basede | 22 (23) | 13 (28) | 9 (18) | |
| Rituximab/nonanthracycline-basedf | 5 (5) | 3 (6) | 2 (4) | |
| Othersg | 7 (8) | 4 (9) | 3 (6) | |
Abbreviation: ACE, doxorubicin, cyclophosphamide and etoposide; CEOP, cyclophosphamide, epirubicin (⩾70 mg/m2), vincristine and prednisolone; CHOP, cyclophosphamide, doxorubicin, vincristine and prednisolone; COP, cyclophosphamide, vincristine and prednisolone; CNOP, cyclophosphamide, mitoxantrone, vincristine and prednisolone; DLBCL, diffuse large B-cell lymphoma; ECOG, Eastern Cooperative Oncology Group; HP, H. pylori; IPI, International Prognostic Index; LDH, lactate dehydrogenase; PACE, prednisolone-ACE; pCR, complete pathologic remission; PR, partial remission; SD, stable disease; PD, progression; GCB, germinal center B-cell.
Proximal: Middle body, upper body, fundus or cardia; distal: antrum, angle or lower body.
Non-ulcerative lesions: gastritis-like or multiple erosion on infiltrative mucosa, erosions on giant nodular folds or mixed lesions.
Total, stage IIE2/III/IV, 14/23/7; HP-positive, stage IIE2/III/IV, 6/7/1; HP-negative, stage IIE2/III/IV, 8/16/6; stage IV (n=7), four bone marrow involvement, two bone involvement and one malignant pleural effusion.
PR, n=3; HP-positive, n=1; HP-negative, n=2.
Anthracycline-based: CHOP, CEOP, ACE and PACE.
Rituximab/anthracycline-based: rituximab-CHOP or rituximab-CEOP.
Rituximab/nonanthracycline-based: rituximab-COP.
Others: CNOP and COP.